key: cord-1053741-3jl9nt89
authors: García‐Estrada, Christian; Gómez‐Figueroa, Enrique; Alban, Lennyn; Arias‐Cárdenas, Alejandro
title: Optic neuritis after COVID‐19 vaccine application
date: 2021-11-22
journal: Clin Exp Neuroimmunol
DOI: 10.1111/cen3.12682
sha: 264548db800a0eb4c060bbf16b189243adaaa1bc
doc_id: 1053741
cord_uid: 3jl9nt89

As the COVID‐19 pandemic continues to rise, the development of effective vaccines is of crucial importance to prevent further morbidity and mortality. In parallel, some rare adverse events related to COVID‐19 vaccines, have been reported, most of them mild. Here we report the case of a previously healthy 19‐year‐old woman who developed optic neuritis 1 week after single dose of Ad26.COV2.S vaccine with marked improvement after management with steroids. Although causality cannot be confirmed due to lack of a biological marker, this case may help to guide further research for potential pathogenic mechanism.

Coronavirus disease 19 (COVID) caused by SARS-Cov-2 represents a priority health issue since its first reports in November 2019, manifesting with a wide variety of primarily respiratory symptoms ranging from asymptomatic to life-threatening conditions such as severe acute respiratory syndrome with over 4 million deaths worldwide. 1 As the COVID-19 pandemic continues to rise, the development of effective vaccines is of crucial importance to prevent further morbidity and mortality. At the time of writing this manuscript, six COVID vaccines have been granted emergency use by regulatory authorities (AZD1222 (ChAdOx1-S), Sputnik V (Gam-COVID-Vac), Ad26.COV2.S, BBV152, BNT162b2 and mRNA-1273) resulting in nearly 6 

As the COVID-19 pandemic continues to rise, the development of effective vaccines is of crucial importance to prevent further morbidity and mortality. In parallel, some rare adverse events related to COVID-19 vaccines, have been reported, most of them mild. Here we report the case of a previously healthy 19-year-old woman who developed optic neuritis 1 week after single dose of Ad26.COV2.S vaccine with marked improvement after management with steroids. Although causality cannot be confirmed due to lack of a biological marker, this case may help to guide further research for potential pathogenic mechanism.

adverse effects, optic neuritis, SARS-Cov2, vaccination, viral vector vaccine The patient received high dose IV steroids (methylprednisolone 1 g daily for 5 days) with improvement in visual acuity from day 2, with nearly complete resolution at day 5 followed by oral prednisolone (1 mg/kg) on tapering schedule over 4 weeks. On last checkup visual acuity of the left eye was 20/20 and papillitis was resolved.

Here we present the case of a 19-year-old woman with optic neuritis after COVID-19 vaccination. As COVID-19 vaccination spreads worldwide it is expected that side effects of these vac- presentation to autoreactive T cells. 12 We recognize that the good clinical response to steroids highly suggest the possibility of MOG-associated disease (MOGAD).

Unfortunately, anti-MOG antibodies were not commercially available. Nevertheless, we cannot ignore the strong temporal relation of the vaccine and the potentially immune mechanisms triggered by its components.

Our rationale is that the viral vector vaccine may access the cerebral neuronal pathways to replicate and trigger a pro-inflammatory response resulting in optic neuritis. Despite these hypotheses, we are aware of the difficulty to establish causality between vaccination and optic neuritis, nevertheless, the close temporal association since vaccine application to symptoms initiation strongly suggest common mechanisms.

We present the case of a previously healthy 19-year-old woman who developed optic neuritis with close temporal association to SARS-Cov-2 vaccination. Although causality cannot be confirmed due to the lack of a biological marker, this case may help to guide further research into a potential pathogenic mechanism.

None declared. Alejandro Arias-Cárdenas https://orcid.org/0000-0002-8874-0964

Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

US Case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

Perspectives on vaccine induced thrombotic thrombocytopenia

Safety and efficacy ofthe ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

ANA investigates: neurological complications of COVID-19 vaccines

Ocular adverse events following vaccination: overview and update

The spectrum of post-vaccination inflammatory CNS demyelinating syndromes

COVID-19 vaccines: modes of immune activation and future challenges

On the molecular determinants of the SARS-CoV-2 attack

Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction